Why the study?
Does bosentan improve exercise tolerance, cardiopulmonary hemodynamics, and time to clinical worsening in patients with WHO functional class III and IV PAH?
Does bosentan improve exercise tolerance, cardiopulmonary hemodynamics, and time to clinical worsening in patients with WHO functional class III and IV PAH?
Bosentan is an effective treatment for WHO functional class III and IV PAH, offering clinical and hemodynamic benefits over placebo and quality of life advantages over epoprostenol.
May support bosentan consideration in severe PAH; leaves open need for RCTs versus modern therapies.
The use of bosentan in patients with WHO functional class III and IV PAH is associated with improved exercise tolerance, cardiopulmonary hemodynamics, and increased time to clinical worsening when compared with placebo. It offers significant advantage in ease of administration and quality of life compared with epoprostenol therapy, with similar efficacy.
No takes yet. Share an insight, caveat, or question.
Kenyon et al. (2003) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: